Opioids and premature biochemical recurrence of prostate cancer: a randomised prospective clinical trial

Imagem de Miniatura
Arquivos
art_RANGEL_Opioids_and_premature_biochemical_recurrence_of_prostate_cancer_2021.PDF (474.68 KB)
Citações na Scopus
13
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCI LTD
Autores
Citação
BRITISH JOURNAL OF ANAESTHESIA, v.126, n.5, p.931-939, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Prostate cancer is one of the most prevalent neoplasms in male patients, and surgery is the main treatment. Opioids can have immune modulating effects, but their relation to cancer recurrence is unclear. We evaluated whether opioids used during prostatectomy can affect biochemical recurrence-free survival. Methods: We randomised 146 patients with prostate cancer scheduled for prostatectomy into opioid-free anaesthesia or opioid-based anaesthesia groups. Baseline characteristics, perioperative data, and level of prostate-specific antigen every 6 months for 2 yr after surgery were recorded. Prostate-specific antigen >0.2 ng ml(-1) was considered biochemical recurrence. A survival analysis compared time with biochemical recurrence between the groups, and a Cox regression was modelled to evaluate which variables affect biochemical recurrence-free survival. Results: We observed 31 biochemical recurrence events: 17 in the opioid-free anaesthesia group and 14 in the opioidbased anaesthesia group. Biochemical recurrence-free survival was not statistically different between groups (P=0.54). Cox regression revealed that biochemical recurrence-free survival was shorter in cases of obesity (hazard ratio [HR] 1.63, confidence interval [CI] 0.16-3.10; p=0.03), high D'Amico risk (HR 1.58, CI 0.35-2.81; P=0.012), laparoscopic surgery (HR 1.6, CI 0.38-2.84; P=0.01), stage 3 tumour pathology (HR 1.60, CI 0.20-299) and N1 status (HR 1.34, CI 0.28-2.41), and positive surgical margins (HR 1.37, CI 0.50-2.24; P=0.002). The anaesthesia technique did not affect time to biochemical recurrence (HR -1.03, CI -2.65-0.49; P=0.18). Conclusions: Intraoperative opioid use did not modify biochemical recurrence rates and biochemical recurrence-free survival in patients with intermediate and high D?Amico risk prostate cancer undergoing radical prostatectomy. Clinical trial registration: NCT03212456.
Palavras-chave
biochemical recurrence, cancer recurrence, multimodal analgesia, opioid, opioid-free anaesthesia, prostatectomy, prostate cancer
URI
https://observatorio.fm.usp.br/handle/OPI/40508
Referências
  1. Al-Hashimi M, 2013, BRIT J ANAESTH, V111, P80, DOI 10.1093/bja/aet153
  2. Bajwa SJS, 2015, J CANCER RES THER, V11, P528, DOI 10.4103/0973-1482.157321
  3. Basiri A, 2018, WORLD J UROL, V36, P609, DOI 10.1007/s00345-018-2174-1
  4. Biki B, 2008, ANESTHESIOLOGY, V109, P180, DOI 10.1097/ALN.0b013e31817f5b73
  5. Boorjian SA, 2011, EUR UROL, V59, P893, DOI 10.1016/j.eururo.2011.02.026
  6. Boysen PG, 2018, OCHSNER J, V18, P121, DOI 10.31486/toj.17.0072
  7. Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
  8. Brown EN, 2018, ANESTH ANALG, V127, P1246, DOI 10.1213/ANE.0000000000003668
  9. Chen DT, 2019, BRIT J ANAESTH, V122, pE157, DOI 10.1016/j.bja.2018.09.030
  10. Chia PMA, 2020, CURR OPIN ANESTHESIO, V33, P512, DOI 10.1097/ACO.0000000000000878
  11. Cookson MS, 2007, J UROLOGY, V177, P540, DOI 10.1016/j.juro.2006.10.097
  12. D'Amico AV, 1998, JAMA-J AM MED ASSOC, V280, P969, DOI 10.1001/jama.280.11.969
  13. Dolan RD, 2018, CRIT REV ONCOL HEMAT, V132, P130, DOI 10.1016/j.critrevonc.2018.09.016
  14. Eipe N, 2016, BJA EDUC, V16, P292, DOI 10.1093/bjaed/mkw008
  15. Forget P, 2011, EUR J ANAESTH, V28, P830, DOI 10.1097/EJA.0b013e32834b7d9a
  16. Frauenknecht J, 2019, ANAESTHESIA, V74, P651, DOI 10.1111/anae.14582
  17. Gu XB, 2016, SCI REP-UK, V6, DOI 10.1038/srep22089
  18. Haram A, 2017, J SURG ONCOL, V115, P470, DOI 10.1002/jso.24523
  19. Himmelseher S, 2005, ANESTHESIOLOGY, V102, P211, DOI 10.1097/00000542-200501000-00030
  20. Ilic D, 2017, COCHRANE DATABASE SY, V9
  21. Julious SA, 2012, STAT MED, V31, P2904, DOI 10.1002/sim.5381
  22. Kampa M, 1997, EUR J PHARMACOL, V335, P255, DOI 10.1016/S0014-2999(97)01213-2
  23. Kelly M, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-244
  24. Kumar K, 2017, ANESTH ANALG, V125, P1749, DOI 10.1213/ANE.0000000000002497
  25. Macleod LC, 2018, UROL ONCOL-SEMIN ORI, V36, DOI 10.1016/j.urolonc.2018.05.016
  26. Malo-Manso A, 2019, CURR PHARM DESIGN, V25, P3011, DOI 10.2174/1381612825666190705183754
  27. McCormick BZ, 2019, INDIAN J UROL, V35, P6, DOI 10.4103/iju.IJU_355_18
  28. Neeman E, 2013, BRAIN BEHAV IMMUN, V30, pS32, DOI 10.1016/j.bbi.2012.03.006
  29. Santoni M, 2019, CANCERS, V11, DOI 10.3390/cancers11091225
  30. Tang CL, 2017, J PAIN RES, V10, P1899, DOI 10.2147/JPR.S139387
  31. Thota RS, 2019, J ANAESTH CLIN PHARM, V35, P441, DOI 10.4103/joacp.JOACP_128_19
  32. Tourinho-Barbosa R, 2018, INT BRAZ J UROL, V44, P14, DOI [10.1590/S1677-5538.IBJU.2016.0656, 10.1590/s1677-5538.ibju.2016.0656]
  33. Wall T, 2019, BRIT J ANAESTH, V123, P135, DOI 10.1016/j.bja.2019.04.062
  34. Wuethrich PY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072873
  35. Wuethrich PY, 2010, ANESTHESIOLOGY, V113, P570, DOI 10.1097/ALN.0b013e3181e4f6ec
  36. Zhang H, 2020, BRIT J ANAESTH, V125, P722, DOI 10.1016/j.bja.2020.07.051
  37. Zhang LJ, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1433-3
  38. Zylla D, 2013, CANCER-AM CANCER SOC, V119, P4103, DOI 10.1002/cncr.28345

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/08
Artigos e Materiais de Revistas Científicas - LIM/55
Carregar mais